Biocept (NASDAQ: BIOC) is in Chapter 7 bankruptcy. This is complete liquidation, the wiping of the company from the Earth. Biocept stock has just risen 87%. This is not a rational reaction to a Chapter 7 filing. Rational would be a rapid and final descent to $0 of course.
But this is what is happening:

Biocept stock price from Google Finance
We’ve talked before of Biocept: “Biocept got a stock issue away. But at the price of wild dilution of extant equity. BIOC raised $5 million which is pretty good. The issue price was $4.25, which given the market price above $5 was a fairly creditable performance. But now think through this again. Biocept had a market capitalization of perhaps $2 million. And it then raised $5 million in new equity. That's a lot of new stock being issued. And, fair enough, they got the issue away. But once people realised what the dilution was going to be like there was always likely to be a stock price fall here. Which is what has just happened.”
The problem with that is that it was back in the spring. And also Biocept was losing $6 million and so on a quarter. So, that was running out by now. To the extent that we’ve got the last published accounts here and reading them we’d expect them to have no money by right about now. Which is, of course, why the Chapter 7 filing.
This is not Chapter 11, time for a reorganisation and negotiation with debtors. This is Chapter 7, the extinction of the firm. The only way there can be value to equity in a Chapter 7 is if the assets are worth more than the debts. But if that’s true then there’s very rarely indeed a Chapter 7 filing.
So, the filing essentially shows that Biocept equity is valueless at which point the BIOC stock price doubles. OK, well, speculation and all that, meme stocks, but we think this is unlikely to last.



